A 42-year-old man with Type 2 diabetes mellitus on metformin monotherapy presents with a 3-month history of progressive fatigue, dyspnea on exertion, and a 4 kg weight loss. His HbA1c is 8.2%. Laboratory investigations reveal: serum creatinine 2.1 mg/dL (eGFR 28 mL/min/1.73 m²), hemoglobin 8.5 g/dL, and elevated reticulocyte count. Peripheral blood smear shows macrocytic red blood cells. All of the following are true regarding the pathophysiology and management of his anemia EXCEPT:

Explanation

## Metformin, B12 Deficiency, and Anemia in Type 2 Diabetes ### Pathophysiology of Metformin-Induced B12 Deficiency **Key Point:** Metformin impairs vitamin B12 absorption in the terminal ileum by interfering with calcium-dependent B12-intrinsic factor complex binding. This occurs in 10–30% of long-term metformin users, though clinically significant deficiency is less common. ### Etiology of Anemia in This Patient | Contributing Factor | Mechanism | Frequency | |-------------------|-----------|----------| | **Metformin-induced B12 malabsorption** | Impaired ileal B12-IF complex absorption | 10–30% of users | | **CKD-related EPO deficiency** | Reduced renal erythropoietin production (eGFR 28) | Universal in moderate CKD | | **Uremia** | Direct bone marrow suppression | Present with eGFR < 30 | | **Chronic inflammation** | Hepcidin-mediated iron sequestration | Common in CKD | ### Why Option 3 is Correct **High-Yield:** Folic acid supplementation ALONE is ineffective for B12 deficiency–induced macrocytic anemia. B12 (cobalamin) is essential for DNA synthesis and myelin formation; folic acid cannot substitute for this function. Folic acid may mask the hematologic manifestations of B12 deficiency (allowing neurologic damage to progress), but will NOT correct the macrocytic anemia. **Clinical Pearl:** The classic teaching is that folic acid supplementation can mask B12 deficiency by correcting the macrocytic anemia while allowing irreversible neurologic damage (subacute combined degeneration of the spinal cord) to progress. Folic acid and B12 are distinct cofactors in one-carbon metabolism; they are not interchangeable. ### Management Algorithm ```mermaid flowchart TD A[Macrocytic anemia + metformin use]:::outcome --> B{Check B12 and folate levels}:::decision B -->|B12 low, folate normal| C[B12 deficiency confirmed]:::outcome B -->|Both low| D[Combined deficiency]:::outcome C --> E[Discontinue/reduce metformin]:::action C --> F[B12 supplementation: IM cyanocobalamin or oral high-dose]:::action D --> G[Supplement both B12 and folate]:::action E --> H[Monitor eGFR; consider alternative agent if CKD progresses]:::action F --> I[Recheck CBC and B12 in 8-12 weeks]:::action ``` **Mnemonic: B12 DEFICIENCY MANAGEMENT** — **B**12 must be replaced (not folate alone), **1** month for IM dosing, **2** months for oral high-dose, **D**iscontinue metformin, **E**valuate neurologic status, **F**olate supplementation if also low, **I**nclude CKD management, **C**heck levels at 8–12 weeks, **I**nvestigate other causes (pernicious anemia, dietary), **E**nsure compliance, **N**eurologic exam mandatory, **C**ontinue monitoring, **Y**early B12 checks if metformin restarted.